natgillin/translations-raw huggingface dataset:
Reported cases of lactic acidosis in patients on metformin have occurred primarily in diabetic patients with impaired renal failure or acute worsening of renal function.
Laktatsidoosi kirjeldatud juhud metformiini saavatel patsientidel on esinenud peamiselt neerupuudulikkusega või järsult halvenenud neerufunktsiooniga suhkurtõvega patsientidel.
Reported cases of lactic acidosis in patients on metformin have occurred primarily in diabetic patients with significant renal failure.
Laktatsidoosi juhud on esinenud peamiselt neil metformiini kasutavatel suhkurtõve patsientidel, kel kaasub oluline neerupuudulikkus.
Reported cases of lactic acidosis in patients on metformin have occurred primarily in diabetic patients with significant renal failure.
Laktatsidoosi teadaolevad juhtumid metformiini saavatel patsientidel on esinenud peamiselt nendel diabeetikutel, kellel oli oluline neerupuudulikkus.
Reported cases of lactic acidosis in patients on metformin have occurred primarily in diabetic patients with significant renal failure.
Metformiini kasutavatel patsientidel kirjeldatud laktatsidoosi juhud on esinenud peamiselt väljendunud neerupuudulikkusega diabeediga patsientidel.
Reported cases of lactic acidosis in patients on metformin have occurred primarily in diabetic patients with significant renal failure.
Metformiini tarvitavatel patsientidel on teatatud laktatsidoosi esinemisest peamiselt raske neerupuudulikkusega diabeetikutel.
Reported commonly in placebo
Teatatud sageli platseeborühmas
Reported rates of recurrent rash following a switch from nevirapine to efavirenz therapy, primarily based on retrospective cohort data from published literature, range from 13 to 18 %, comparable to the rate observed in patients treated with efavirenz in clinical studies. (See section 4.4.)
Korduva lööbe kirjeldatud esinemissagedus pärast üleminekut nevirapiinilt efavirensravile, mis peamiselt põhineb publitseeritud kirjandusest saadud retrospektiivse kohordi andmetel, jääb vahemikku 13...18%, mis on võrreldav kliinilistes uuringutes efavirensiga ravitud patsientidel täheldatud esinemissagedusega. (Vt lõik 4.4.)
Reported rates of recurrent rash following a switch from nevirapine to efavirenz therapy, primarily based on retrospective cohort data from published literature, range from 13 to 18%, comparable to the rate observed in patients treated with efavirenz in clinical studies (see section 4.4).
Korduva lööbe kirjeldatud esinemissagedus pärast üleminekut nevirapiinilt efavirensravile, mis peamiselt põhineb publitseeritud kirjandusest saadud retrospektiivse kohordi andmetel, jääb vahemikku 13...18%, mis on võrreldav kliinilistes uuringutes efavirensiga ravitud patsientidel täheldatud esinemissagedusega. (Vt lõik 4.4.)
Reported rates of recurrent rash following a switch from nevirapine to efavirenz therapy, primarily based on retrospective cohort data from published literature, range from 13 to 18%, comparable to the rate observed in patients treated with efavirenz in clinical studies. (See section 4.4.)
Korduva lööbe kirjeldatud esinemissagedus pärast üleminekut nevirapiinilt efavirensravile, mis peamiselt põhineb publitseeritud kirjandusest saadud retrospektiivse kohordi andmetel, jääb vahemikku 13...18%, mis on võrreldav kliinilistes uuringutes efavirensiga ravitud patsientidel täheldatud esinemissagedusega. (Vt lõik 4.4.)
Reported side effects following the use of OPTISON:
OPTISON’i manustamisega seotud reaktsioonid:
Reported very commonly in placebo
Teatatud väga sageli platseeborühmas
reported with a higher incidence (very common) in patients who received two concurrent injections of Xiapex in the same hand compared with subjects treated with up to three single injections in the Phase 3 placebo-controlled pivotal studies in Dupuytren’s contracture.
teatatud suuremast esinemissagedusest (väga sage) patsientidel, kes said Xiapexi kaks samaaegset süstet samasse kätte, võrreldes osalejatega, kellele süstiti kuni kolm üksikannust Dupuytreni kontraktuuri olulise tähtsusega, III faasi platseebokontrolliga uuringutes.
reported11
riskifaktorid.1
reported11
riskifaktorid.11
Reporting of adverse effects
Kõrvaltoimetest teavitamine
Reporting of medication errors or any side effects
Kõikidest ravivigadest või mistahes kõrvaltoimetest tuleb teavitada
Reporting of medication errors or any side effects.
Teavitamine ravivigadest või mis tahes kõrvaltoimetest.
Reporting of medication errors or any side effects.
Teavitamine ravivigadest või mis tahes kõrvaltoimetestt.
Reporting of serious adverse drug reactions
Tõsistest ravimi kõrvaltoimetest teatamine
Reporting of serious adverse events(reminder aid)
Tõsistest kõrvaltoimetest teatamine (meelespea)
Reporting of serious adverse reactions
Tõsistest kõrvaltoimetest teavitamine
Reporting of side effe cts
Kõrvaltoime test teavitamine
Reporting of side effects
Kõrvaltoimetest teatamine.
Reporting of side effects.
Kõrvaltoimetest teavitamine
Reporting of suspected adverse reactions
dasabuviiriga.
Reporting of suspected adverse reactions
Kahtlustatavatest kõrvalnähtudest teadaandmine
Reporting of suspected adverse reactions
Kõrvaltoimetest teavitamine
Reporting of suspected adverse reactions
UVõimalikest kõrvaltoimetest teavitamine
Reporting of suspected adverse reactions
Voimalikest korvaltoimetest teavitamine
Reporting of suspected adverse reactions
Võimalikest kõrvaltoimetest teatavitamine
Reporting of suspected adverse reactions:
Võimalikest kõrvaltoimetest teavitamine
Reporting suspected adverse reactions after authorisation of the medicial product is important.
Ravimi võimalikest kõrvaltoimetest on oluline teavitada ka pärast ravimi müügiloa väljastamist.
Reporting suspected adverse reactions after authorisation of the medicinal product is important.
Ravimi voimalikest korvaltoimetest on oluline teavitada ka parast ravimi muugiloa valjastamist.
Reporting suspected adverse reactions afterauthorisation of themedicinal product is important.
Ravimi võimalikest kõrvaltoimetest on oluline teavitada ka pärast ravimi müügiloa väljastamist.
reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.
Teavitades aitate saada rohkem infot ravimi ohutusest.
Reporting to be fortnightly for the first 3 months of the pandemic.
Pandeemia 3 esimese kuu jooksul peab raporteerima iga kahe nädala tagant.
Reporting to be fortnightly for the first 3 months of the pandemic.
Pandeemia esimese kolme kuu jooksul tuleb aruandeid esitada iga kahe nädala järel.
Reporting to be monthly for the first 6 months.
Aruandlus on igakuine esimesel 6 kuul.
Reporting to be monthly for the first 6 months.
Esimesel 6-l kuul tuleb aruanne esitada igal kuul.
Reporting to be monthly for the first 6 months.
Raporteerima peab esimese 6-kuu jooksul iga kuu.
Reportng suspected adverse reactions after authorisation of the medicinal product is important.
Ravimi võimalikest kõrvaltoimetest on oluline teavitada ka pärast ravimi müügiloa väljastamist.
Reports - with each
vahearuanded
Reports from published literature confirmed that methylthioninium chloride is effective in treating methaemoglobinaemia that has been caused by exposure to a medicine or chemical in adults and children.
Kirjanduses avaldatud andmed kinnitasid, et metüültioniinkloriid on kokkupuutest ravimite või kemikaalidega tekkinud methemoglobineemia ravis efektiivne täiskasvanutel ja lastel.
Reports from the sub-
aruanded tuleb
Reports have been received from post-approval marketing experience in association with the use of Enurev Breezhaler.
Teated on kogutud turuletulekujärgselt seoses Enurev Breezhaler’i kasutamisega.
Reports have been received from post-approval marketing experience in association with the use of Seebri Breezhaler.
Teated on kogutud turuletulekujärgselt seoses Seebri Breezhaler’i kasutamisega.
Reports have been received from post-approval marketing experience in association with the use of Tovanor Breezhaler.
Teated on kogutud turuletulekujärgselt seoses Tovanor Breezhaler’i kasutamisega.
Reports have included fatal and life-threatening infections and sepsis.
Teated on sisaldanud surmaga lõppevaid ning eluohtlikke infektsioone ja sepsist.
Reports in the literature indicate that treatment of another indication with dopaminergic medicinal products can result in augmentation.
Kirjanduses avaldatud andmetel põhinevalt võib teise näidustuse ravi dopamiinergiliste ravimitega põhjustada sümptomaatika progresseerumist.
Reports in the literature indicate that treatment of another indication with dopaminergic medicinal products can result in augmentation.
Kirjanduses avaldatud andmetel põhinevalt võib teise näidustuse ravi dopaminergiliste ravimitega põhjustada sümptomaatika progresseerumist.
reports of abnormal liver tests values,
maksanäitajate normist erinevad väärtused,
Reports of extravasation with subsequent infusion site reactions including e.g. infusion site dermatitis, infusion site desquamation, and infusion site ulcer have been received.
Ekstravasatsioonile järgnenud infusioonikoha reaktsioone kirjeldavad teatised hõlmavad näiteks infusioonikoha dermatiiti, infusioonikoha ketendust ning haavandeid.
Reports of gastrointestinal perforation on tocilizumab were primarily reported as complications of diverticulitis including generalised purulent peritonitis, lower gastrointestinal perforation, fistulae and abscess.
Seedetrakti perforatsiooni juhtudest teatati totsilizumabi puhul peamiselt divertikuliidi komplikatsioonidena, sh generaliseerunud mädane peritoniit, seedetrakti alumise osa perforatsioon, fistul ja abstsess.
Reports of lack of effect, mainly in prophylaxis patients, have been received in the clinical trials and in the post-marketing setting for ReFacto.
ReFacto kliinilistes uuringutes ja turustamisjärgsel perioodil on olnud teateid ravimi ebapiisavast toimest, peamiselt ravimit profülaktilistel eesmärkidel saanud patsientidel.
Reports of lupus and lupus-like syndromes, however, remain uncommon (see section 4.4).
Luupusesarnaseid kliinilisi nähte ilmnes vaid aeg-ajalt (vt lõik 4.4).
Reports of overdoses with oseltamivir have been received from clinical trials and during post- marketing experience.
Oseltamiviiri üleannustamisest on teatatud kliinilistes uuringutes ja turuletulekujärgselt.
Reports of serious infection have been received in post-marketing surveillance including device- related infection, device-related sepsis, pneumonia, sepsis, bacteraemia, and urinary tract infection.
Turustusjärgsel jälgimisel on teatatud tõsistest infektsioonidest, sh seadmega seotud infektsioonid, seadmega seotud sepsis, kopsupõletik, sepsis, baktereemia ja kuseteede põletik.
Reports of various malignancies (including breast and lung carcinoma and lymphoma) have also been received in the postmarketing period (see section 4.4).
Erinevatest pahaloomulistest kasvajatest (sh rinna- ja kopsuvähk ning lümfoom) on teatatud ka ravimi turustamisjärgsel perioodil (vt lõik 4.4).
Reports of various malignancies (including breast and lung carcinoma and lymphoma) have also been received in the postmarketing period (see section 4.4).
Turuletulekujärgsel perioodil on teatatud ka erinevatest pahaloomulistest kasvajatest (sh rinna- ja kopsuvähk ning lümfoom) (vt lõik 4.4).
Reports on recruitment progress of the patient surveillance database will be analysed and reported to the CHMP at the time of PSURs (for safety) and of the Annual Re- assessments (for efficacy and safety).
Patsientide järelevalve andmebaasi uuendamise aruandeid analüüsitakse ja esitatakse inimravimite komiteele samaaegselt perioodilise ohutusaruandega (ohutuse andmed) ja iga-aastase kordusekspertiisiga (efektiivsuse ja ohutuse andmed).
Reproducti ve system and breast disorders
Reproduktiiv se süsteemi ja rinnanäärme häired
Reproduction and development studies have demonstrated a potent effect on foetal loss with a high rate observed in rats and mice (180 pg/ml and 30 pg/ml plasma, respectively) at exposures 1.2 to 6 times the clinical exposure (up to 25 pg/ml).
Paljunemisvõime ja arengu uuringutes on rottidel ja hiirtel (plasmakontsentratsioonidel vastavalt 180 pg/ml ja 30 pg/ml) näidatud toimet loote surmade olulisele sagenemisele, kui ravimit manustati kliiniliselt kasutatavast annusest 1,2-6 korda suuremas annuses (kuni 25 pg/ml).
Reproduction is authorised provided the source is acknowledged monitored included weight gain, mortality as well as faecal and nasal shedding.
Reproduction is authorised provided the source is acknowledged ninast.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledg
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. agregatsiooni (kokkukleepumise) tõttu.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. aktiivseteks toimeaineteks.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. bakteri Bordetella bronchiseptica inaktiveeritud rakke.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. blokeerivad pöördtranskriptaasi aktiivsust.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. entakapooni.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. geeniteraapiaravimite hulka kuuluv uudne ravim.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. hästi.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. hävitamise koordineerimises.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. inimese VIII hüübimisfaktor.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. jaoks olenevalt tema sapphapete profiilist.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. jälgida.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. kasutama ettevaatlikult, vältides bakterite sattumist geeli.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. kasvu.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. kohandatakse olenevalt patsiendi ravivastusest ja ravimitaluvusest.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. kontsentraadina.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. kopsuhaiguse raviks.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. lihased.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. menopausijärgses eas naistel naissuguhormooni östrogeeni sisalduse vähenemise tõttu.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. mida need viirused esile kutsuvad.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. mõju.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. neerutalitlust ja ravimi teatud võimalikke kõrvaltoimeid.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. ning ravi ajal tehtavate vereanalüüside tulemustest.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. olenevalt patsiendi ravivastusest.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. on olemas võimalike südame- või kopsuprobleemide või allergiareaktsioonide järgse elustamise vahendid.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. osaleb osteoklastide ehk luukoe lagunemises osalevate rakkude aktiveerimises.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. patsiendile kasu.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. põletikuprotsessis.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. ravimeid.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. retseptoritele), mis blokeerivad hormooni eritumist.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. saadud T-rakud teistest siiriku rakkudest.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. seda toodab bakter, millele on lisatud filgrastiimi teket võimaldav geen (DNA).
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. seejärel eritub organismist väljaheitega.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. sisalduvaid bakteriosi võõraks ja tekitab nende vastu antikehi.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. südamelihasel lõdvestuda, parandades südamelihase verevarustust ja leevendades stenokardia sümptomeid.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. talutavad.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. tavaliselt esinev sisaldus).
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. tokofersolaani ligikaudu kaks aastat.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. tõttu.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. vaja annust vähendada.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. vereliistakute – agregatsiooni (kokkukleepumise) tõttu.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. vähendada.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. vähendavat annust kohandada.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. väikese koguse veega või toiteseguga.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. või triasolaamiga (samuti unetuseravimid).
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. ühesuguse kiirusega.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged..
Reproduction is authorised provided the source is acknowledged.
Reprodutseerimine on lubatud allikale viitamisel.
Reproduction is authorised provided the source is acknowledged.
Üksikasjalik teave on pakendi infolehel.
Reproduction is authorised provided the source is acknowledged. a fifth if patients are taking the medicine valproate for another condition at the same time as they are taking Xyrem.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. able to produce antibodies more quickly when it is exposed to any of these virus strains.
Reproduction is authorised provided the source is acknowledged. termelésére, amikor az említett vírustörzsek valamelyikével kerül kapcsolatba.
Reproduction is authorised provided the source is acknowledged. action of viral DNA and RNA, which are needed for viruses to survive and multiply.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. active ingredient, betamethasone acetate, is a corticosteroid, a medicine that reduces inflammation and pain.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. active substance tenofovir in the body.
Reproduction is authorised provided the source is acknowledged. pöördtranskriptaasiinhibiitorite lähedalt seotud tüübid.
Reproduction is authorised provided the source is acknowledged. adequately controlled on metformin alone who start taking Komboglyze should continue to receive the same dose of metformin they were previously taking.
Reproduction is authorised provided the source is acknowledged. metformiiniga ei ole vere glükoosisisaldus piisavalt reguleeritud, hakkavad võtma Komboglyzet, peavad nad saama sama annuse metformiini kui varem.
Reproduction is authorised provided the source is acknowledged. adjusted to suit the patient’s diet, physical activity and lifestyle.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. adults with MDS/MPD who have re-arrangements of the gene for platelet-derived growth factor receptor (PDGFR);
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. advanced hypereosinophilic syndrome (HES) or chronic eosinophilic leukaemia (CEL), diseases in which eosinophils (another type of white blood cell) start growing out of control.
Edasiarenenud hüpereosinofiilia sündroom (HES) või krooniline eosinofiilne leukeemia (CEL) – haigused, mille korral eosinofiilid (teatud leukotsüüdid) hakkavad takistamatult vohama.
Reproduction is authorised provided the source is acknowledged. altogether if side effects are severe.
Reproduction is authorised provided the source is acknowledged. tõsiste kõrvalnähtude korral ravi katkestada.
Reproduction is authorised provided the source is acknowledged. always be given to patients in a place where these reactions can be managed immediately if they occur.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. amount of food or drink immediately before swallowing it.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. anastrozole (another anticancer medicine) taken at a dose of 1 mg every day in 851 women.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. animals are exposed to Erysipelothrix rhusiopathiae bacteria, the immune system will be able to respond more quickly.
Reproduction is authorised provided the source is acknowledged. puutuvad hiljem Erysipelothrix rhusiopathiae bakteritega uuesti kokku, tekivad antikehad kiiremini.